Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review
| Autor: | Yesne Alici, Meredith MacGregor, Elie Isenberg-Grzeda, Ngai Chow, Konstantina Matsoukas, Diane Reidy-Lagunes |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Drug-Related Side Effects and Adverse Reactions Population Neuroendocrine tumors Article 03 medical and health sciences 0302 clinical medicine Quality of life Internal medicine medicine Humans 030212 general & internal medicine education General Nursing Depression (differential diagnoses) Malignant Carcinoid Syndrome education.field_of_study Depression business.industry General Medicine medicine.disease Antidepressive Agents Carcinoma Neuroendocrine Psychiatry and Mental health Clinical Psychology 030220 oncology & carcinogenesis Anxiety Antidepressant medicine.symptom business Carcinoid syndrome |
| Zdroj: | Palliat Support Care |
| ISSN: | 1478-9523 1478-9515 |
| DOI: | 10.1017/s147895152000005x |
| Popis: | ObjectiveSymptoms of depression and anxiety are common in neuroendocrine tumor (NET), yet controversy exists over whether serotonin-mediated antidepressants (SAs) are safe in this population. We sought to address this knowledge gap.MethodFollowing PRISMA guidelines, we conducted a systematic review to identify NET patients who were prescribed SA.ResultsWe identified 15 articles, reporting on 161 unique patients, 72 with carcinoid syndrome (CS) and 89 without. There was substantial agreement between reviewers at the full-text stage (κ = 0.69). Three of the articles, all with low risk of bias, accounted for most of the cases (149/161; 93%). Among the 72 NET patients with CS prior to antidepressant usage, CS was exacerbated in 6 cases (8%), only 3 (4%) of whom chose to discontinue the antidepressant. The remaining 89 patients had no prior CS symptoms, and none developed CS following antidepressant usage. Overall, no instances of carcinoid crisis or death were reported.ConclusionsWe found no evidence for serious adverse outcomes related to SA usage in NET patients. Previous authors have recommended avoiding antidepressants in NET, but our findings do not support those recommendations. Oncologists should nonetheless monitor for symptom exacerbation when prescribing SA to patients with NET. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|